Valley Medical Research
Meenakshi Patel, MD, Principal Investigator

MCI (Mild Cognitive Impairment) and Mild AD (Alzheimer’s Disease) Study

- Mission AD Study sponsored by Eisai. Ages 50-85, Cognitive score >24/30, must be able to have an MRI, can be AD drug naïve or on any AD meds, 2 year treatment period, oral treatment targets the build-up of Amyloid plaque. 15 visits to the clinic, 1 PET, 3 MRIs at Kettering Medical Center. Upon completion, the subject may go into the 12 month extension where all subjects get the actual drug, no placebo involved.

Mild to Moderate AD Study

- Suven Study sponsored by Suven. Ages 50-85, cognitive assessment between 12-20/30, must be on Aricept and Namenda, have a diagnosis of AD for 1 year, 6 month treatment period, oral treatment potentiates (enhances) the effects of Aricept, 6 visits to the clinic, 1 MRI or CT scan at Kettering Medical Center.

Agitation in AD Studies

- Triad Study sponsored by Avanir. Ages 50-90, cognitive score between 6-26/30, must have moderate agitation within 2 weeks prior to screening, can be on any AD meds, 6 month treatment period, oral study drug is Nuedexta (FDA approved for another disease), 8 visits to the clinic. Upon completion, the subject may go into the 12 month extension where all subjects get the actual drug, no placebo involved.

- 201 Agitation Study sponsored by Intracellular Therapies. Age >50, Cognitive score between 8-26/30, must have moderate agitation or aggression within 2 weeks prior to screening, can be on any AD meds but must stop all anti-psychotics prior to starting study drug, 4 week treatment period, 6 visits to the clinic. Upon completion, the subject may go into the 6 month extension where all subjects get the actual drug, no placebo involved.

All studies require a caregiver or study partner, all studies have a placebo, and all studies compensate for time and travel.

Please call Cyndi Whittington, RN, MS for more information 937-208-8298